Interacciones medicamentosas, alteraciones en la absorción de micronutrientes y demencia senil con el consumo prolongado de inhibidores de la bomba de protones

Alfredo Hierro González, Carolina Monserrath Lema Ramos

Texto completo:

PDF

Resumen

Introducción: Los inhibidores de la bomba de protones (IBP) se encuentran entre los medicamentos de mayor uso a nivel mundial y aunque en general son un grupo de medicamentos seguros, cada día se referencia más en la literatura internacional la ocurrencia de reacciones adversas con su uso a largo plazo.

Objetivo: Describir algunas de las reacciones adversas con el uso a largo plazo de los IBP.

Métodos: Mediante una revisión narrativa exhaustiva de la bibliografía internacional se realiza una descripción del efecto de este grupo de medicamentos en la absorción de algunos micronutrientes, interacción con un grupo de medicamentos, así como su posible asociación con la demencia senil tipo Alzheimer.

Conclusión: Aunque se ha sugerido la asociación entre el consumo de IBP y diversas reacciones adversas a largo plazo, la calidad de la evidencia para sustentar el incremento del riesgo para cada una de ellas es heterogénea y en muchos casos de calidad marginal.

Palabras clave

inhibidores de la bomba de protones; reacciones adversas; efectos secundarios; bencimidazoles; antisecretores gástricos

Referencias

de la Coba C, Arguelles Arias F, Martín de Argila C, Júdez J, Linares A, Ortega Alonso A, Rodríguez E, Rodríguez Téllez M, Vera I, et al. Efectos adversos de los inhibidores de la bomba de protones: revisión de evidencias y posicionamiento de la Sociedad Española de Patología Digestiva. RevEspEnfermDig. [Internet] 2016 [citado 2018 Nov 16];108(4):207-24. Disponible en: http://scielo.isciii.es/pdf/diges/v108n4/es_especial.pdf

Oscanoa E. Teodoro. Seguridad de los Inhibidores de la Bomba de Protones. RevGastroenterol. [Internet] 2011;31:49-55 [citado el 8 dic. 2019]. Disponible en: http://perurevista.com/index.php/gastro/article/view/2314/1911

Cardona Ospina JA, Medina Morales DA, Rodríguez Morales AJ, Machado Alba JE. Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia. [Revisión de Tema]. [Internet] 2016 [citado el 21 de febrero 2020]. Disponible en:http://www.scielo.org.co/pdf/rcg/v31n4/v31n4a10.pdf

Aguilera Castro L, Martín de Argila de Prados M, Albillos Martínez A. Consideraciones prácticas en el manejo de los inhibidores de la bomba de protones. [Revisión] RevEspEnfermDig. [Internet] 2016 [citado 2018 Nov 16]. Disponible en: http://scielo.isciii.es/pdf/diges/v108n3/es_revision.pdf

SimoMiñana J. Use of prescription drugs in Spain and Europe. AtenPrimaria. 2012[citado el 21 de febrero 2020];44:335-47.Available from:https://www.ncbi.nlm.nih.gov/pubmed/22018798

Zink DA, Pohlman M, Barnes M, et al. Long-term use of acid suppression started inappropriately during hospitalization. Aliment PharmacolTher 2005[cited 2020 jam 21];21:1203-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15882240DOI: 10.1111/j.1365-2036.2005.02454.x

Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010[cited 2019 jam 11];49:2561-8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605652DOI: 10.2169/internalmedicine.49.4064

Arnold J., Bruning K, Riquelme A y Vargas JI. Eventos adversos asociados al uso de inhibidores de bomba de protones: un análisis crítico de la evidencia actual. Gastroenterol. latinoam 2018[citado el 21 de feb. 2020];29(2):61-8 Disponible en: https://www.bing.com/search?q=Gastroenterol+latinoam+2018%3B29%282%29%3A+61-8&pc=MOZI&form=MOZTSB

Avinash K. Nehra, Jeffrey A. Alexander, Conor G. Loftus, and VandanaNehra. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. [internet] February 2018 [cited 2019 Jam 9];93(2):240-246. Available from: https://doi.org/10.1016/j.mayocp.2017.10.022www.mayoclinicproceedings.org

Urquizo Ayala G, Arteaga Coarite R. Uso de Inhibidores de la Bomba de Protones en la práctica clínica:¿terapia adecuada para todos?.RevMed La Paz [internet] Enero - Junio 2018[cited 2019 Jam 12];24(1):70-7 Disponible en: www.scielo.org.bo/pdf/rmcmlp/v24n1/v24n1_a11.pdf

Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. Editorial Office of Gut and Liver; 2017 Jan 15[cited 2019 jul 14];11(1):27–37.Available from:https://emedicine.medscape.com/article/181753-medication

Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018 Feb;93(2):240–6.Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533960

Aronson JK. Inhibiting the proton pump: mechanisms, benefits, harms, and questions. BMC 2016 Nov 9[cited 2019 Jam 12];14(1):172. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27825384

Linder L, Tamboue C, Clements JN.Drug-Induced Vitamin B12 Deficiency: A Focus on Proton Pump Inhibitors and Histamine-2 Antagonists. J PharmPract 2017 [cited 2019 dec 21];30:639-42. Availablefrom:

Lam JR, Schneider J, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 2013 [cited 2020 fev 12];310:2435-42. Available from:https://jamanetwork.com/journals/jama/article-abstract/1788456 doi:10.1001/jama.2013.280490

Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013; 14(1):150.

Force R, Meeker A, Cady P, Culbertson VL, Force WS, Kelley CM. Increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003 [cited 2019 nov29];37:490-3. Available from:https://journals.sagepub.com/doi/abs/10.1345/aph.1c037https://doi.org/10.1345/aph.1C037

Evatt ML, Terry PD, Ziegler TR, Oakley GP. Association between vitamin B12-containing supplement consumption and prevalence of biochemically defined B12 deficiency in adults in NHANES III (Third National Health and Nutrition Examination Survey). PublicHealthNutr. 2010 [citec 2019 nov 29];13(1):25-31.Availablefrom:DOI: https://www.cambridge.org/core/journals/public-health-nutrition/article/association-between-vitamin-b12containing-supplement-consumption-and-prevalence-of-biochemically-defined-b12-deficiency-in-adults-in-nhanes-iii-third-national-health-and-nutrition-examination-survey/76081AED594DCC266FB83D629E48E9EEhttps://doi.org/10.1017/S1368980009990279

Dharmarajan TS, Kanagala MR, Murakonda P, et al. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med DirAssoc 2008 [cited 2019 nov 29];9:162-7. DOI: 10.1016/j.jamda.2007.10.004

Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B-12 deficiency in older adults. J ClinEpidemiol 2004 [cited 2019 nov 22];57:422-8. DOI: 10.1016/j.jclinepi.2003.08.015

Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 1994 [cited 2020 jam 28];120:211-5. DOI: 10.7326/0003-4819-120-3-199402010-00006

Mitchell SL, Rockwood K. The association between antiulcer medication and initiation of cobalamin replacement in older persons. J ClinEpidemiol 2001 [cited 2019 dec 21];54:531-4. DOI: 10.1016/S0895-4356(00)00340-1

Koop H. Review article: Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Aliment PharmacolTher 1992 [cited 2019 oct 21];6:399-406. DOI: 10.1111/j.1365-2036.1992.tb00553.x

Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term Acid suppression with proton pump inhibitors. Aliment PharmacolTher 2008 [cited 2019 oct 21];27:1110-21. DOI:10.1111/j.1365-2036.2008.03658.x

Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety Of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment PharmacolTher 2015 [cited 2019 dec 16];41:1162-74. DOI: 10.1111/apt.13194

Stabler SP. Vitamin B-12 Deficiency. N Engl J Med 2013 [cited 2020 jam 12];368:149-60. Available from:

Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006 [cited 2019 dec 21];355:1834-6. DOI: 10.1056/NEJMc066308

Sumukadas D, McMurdo MET, Habicht D. Proton pump inhibitors are associated with lower magnesium levels in older people with chronic kidney disease. J Am GeriatrSoc 2012 [cited 2019 ago 15];60:392-3. DOI: 0.1111/j.15325415.2011.03808.x

Sharara AI, Chalhoub JM, Hammoud N, et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a managed care cohort. ClinGastroenterolHepatol 2016 [cited 2019 dec 14];14:317-21. DOI: 10.1016/j.cgh.2015.10.012

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Riesgo de hipomagnesemia asociado a los medicamentos inhibidores de la bomba de protones (IBP). Ref. MUH (FV), 27/2011. [internet] 2011[visitado 23/12/15]. [3 páginas] Accesible en: http://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2011/docs/NI-MUH_27-2011.pdf.

FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Washington, DC: US. Food and Drug Administration; 2011. Available from:http://www.fda.gov/Drugs/DrugSafety/ucm213206.htm.

Administration TG. Risk of hypomagnesaemia with proton pump inhibitors. Medicines Safety Update Vol 2, Number 3. Australian Prescriber 2011 [cited 2019 dec 12];34:81. Availablefrom: https://www.tga.gov.au/publicationissue/medicines-safety-update-vol-2-no-3-june-2011

Gau J-T, Yang Y-X, Chen R, et al. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf 2012 [cited 2020 fev 2];21:553-9. DOI:10.1002/pds.3224

Reimer C. Safety of long-term PPI therapy. Best Pract Res ClinGastroenterol. 2013; 27(3):443-54

Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010 [cited 2020 fev 2];139(4):1115-27. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0016508510012412https://doi.org/10.1053/j.gastro.2010.08.023

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosisrelated fractures. CMAJ 2008 [cited 2020 jam 31];179(4):319-26. Available from:DOI: https://doi.org/10.1503/cmaj.071330

Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. ArchInternMed 2011 [cited 2019 dec 21];171:9981004. DOI: 10.1001/archinternmed.2011.20

Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif Tissue Int 2014 [cited 2020 fev 5];94:597-607. DOI: 10.1007/s00223-014-9855-6

Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008 [cited 2019 dec 21];28:951-9. DOI: 10.1592/phco.28.8.951

Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. OsteoporosInt. 2016 [cited 2020 jam 6];27(1):339-347.Availablefrom:

Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture. JAMA. 2006 [cited 2019 dec 20];296(24):2947–53. Availablefrom:https://jamanetwork.com/journals/jama/article-abstract/204783doi:10.1001/jama.296.24.2947

Abraham NS. Proton pump inhibitors: potential adverse effects. Current Opinion in Gastroenterology. 2012 Nov 1[cited 2019 dec 16];28(6):615–20. Available from:https://journals.lww.com/co-gastroenterology/fulltext/2012/11000/Proton_pump_inhibitors___potential_adverse_effects.13.aspxdoi: 10.1097/MOG.0b013e328358d5b9

Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies. The American Journal of Gastroenterology. 2011 Apr 12 [cited 2019 dec 21];106(7):1209–18. Available from:https://journals.lww.com/ajg/Abstract/2011/07000/Proton_Pump_Inhibitors_and_Risk_of_Fracture__A.8.aspxdoi: 10.1038/ajg.2011.113

Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010 Jul [cited 2020 fev 12];139(1):93–101. Available from:https://www.sciencedirect.com/science/article/abs/pii/S0016508510004889https://doi.org/10.1053/j.gastro.2010.03.055

Bahtiri E, Islami H, Hoxha R, Qorraj-Bytyqi H, Rexhepi S, Hoti K, et al. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors. J Bone Miner Metab. 12 ed. 2015 Jul 25 [cited 2020 fev 12];34(5):571–9.Available from:

Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.Mayo Clin Proc. 2013 Oct [cited 2019 nov 29];88(10):1085–90. Available from:https://www.sciencedirect.com/science/article/abs/pii/S0025619613005648 https://doi.org/10.1016/j.mayocp.2013.07.004

Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid MK, Judge A, Nogués X, et al. Predictors of fracture while on treatment with oral bisphosphonates: A population based cohort study. J Bone Miner Res 2014 [cited 2019 nov 25];29(1):268-74. DOI: 10.1002/jbmr.2011

Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O’Brien KO, Proctor DD, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial. J Bone Miner Res 2010 [cited 2020 fev 12];25:2205-11. DOI: 10.1002/jbmr.108

Jo Y, Park E, Ahn SB, Jo YK, Son B, Kim SH, Park YS, and Kim HJ. A proton pump inhibitor’s effect on bone metabolism mediated by osteoclast action in old age: A prospective randomized study. GutLiver 2015 [cited 2019 oct 20];9(5):607-14. DOI: 10.5009/gnl14135

Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors whenused with clopidogrel: Meta-analysis. Int J Cardiol 2013 [cited 2019 dec 20];167:965-74. DOI: 10.1016/j.ijcard.2012.03.085

Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, et al. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment PharmacolTher 2012 [cited 2019 oct 20];35:165-74. Available from:https://doi.org/10.1111/j.1365-2036.2011.04890.x

Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013 [cited 2020 fev 20];34:1708-13.DOI: 10.1093/eurheartj/eht042

Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann PharmacolTher 2009 [cited 2020 jam 15];43:1266-74.Availablefrom:https://journals.sagepub.com/doi/abs/10.1345/aph.1M051https://doi.org/10.1345/aph.1M051

Goodman SG, Clare R, Pieper KS, Nicolau JC, Storey RF, Cantor WJ, et al. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor insights from the platelet inhibition and patient outcomes trial. Circulation 2012 [2019 dec 12];125:978-86. DOI: 10.1161/CIRCULATIONAHA.111.032912

Food and Drug Administration. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole (27 oct). 2010[cited 2019 dec 23]. Availablefrom: http://www.fda.gov/Drugs/DrugSafety/ucm231161.htm.

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. RevEspCardiol (Engl Ed) 2018 [cited 2020 mar 12];71:42.Availablefrom:https://doi.org/10.1016/j.recesp.2017.11.014

Xie Y, Bowe B, Li T, Xian H, Yan Y, AL-Aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States Veterans. BMJ 2017 [cited 2019 nov 28];7:e015735.Availablefrom:http://dx.doi.org/10.1136/bmjopen-2016-015735https://bmjopen.bmj.com/content/7/6/e015735.abstract

Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 2016 [cited 2020 mar 11];73(4):410-6. Available from:https://jamanetwork.com/journals/jamaneurology/article-abstract/2487379doi:10.1001/jamaneurol.2015.4791

Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry ClinNeurosci 2015 [cited 2019 dec 25];265:419-28. Available from:https://link.springer.com/article/10.1007/s00406-014-0554-0

Wise J.Proton pump inhibitors may be linked to dementia risk BMJ 2016 [cited 2019 jam 2];352:i972 DOI: 10.1136/bmj.i972

Torjesen I. Proton pump inhibitor use does not raise dementia and Alzheimer’s risk, study suggests. BMJ 2017 [cited 2019 oct 25];357:j3063 DOI: 10.1136/bmj.j3063

Enlaces refback

  • No hay ningún enlace refback.


Bookmark and Share


Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.